RhIGF-I/rhIGFBP-3 ( DrugBank: rhIGFBP-3 )

1 disease

ID	Disease name (Link within this page)	Number of trials
113	Muscular dystrophy	2

113. Muscular dystrophy

Clinical trials : 646 / Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00577577 (ClinicalTrials.gov)	December 2007	18/12/2007	Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insuli ...	A Placebo Controlled, Randomized, Double-Blind Phase II Clinical Trial to Evaluate Tolerability, Saf ...	Myotonic Dystrophy Type 1	Drug: rhIGF-I/rhIGFBP-3;Drug: placebo	Insmed Incorporated	Muscular Dystrophy Association	Active, not recruiting	21 Years	65 Years	Both	60	Phase 2	United States
2	NCT00233519 (ClinicalTrials.gov)	November 2005	3/10/2005	Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insuli ...	Effects of SomatoKine (Iplex) (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1)	Myotonic Dystrophy	Drug: SomatoKine/IPLEX	University of Rochester	National Institute of Neurological Disorders and Stroke (NINDS);Imsmed Incorporated	Completed	21 Years	60 Years	All	17	Phase 1/Phase 2	United States

First Previous1Next Last